Journal: medRxiv

Article Title: Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19

doi: 10.1101/2022.03.10.22272123

Figure Lengend Snippet: (A ) STAT1 expression in the lung after 4-day culture in the presence of IFN beta with or without hydrocortisone (HC). ( B) pSTAT1 expression in the same specimens as in A. ( C) Example photomicrographs showing higher STAT2 expression in a TT patient than in a CT patient and the effect of HC on its nuclear translocation. Most STAT2 remains in the cytoplasm of the CT patients, whereas nuclear expression is prominent in the TT patient. Indicated insets are shown in the bottom row. Arrows. ( D ) Combined results of all patients noting that two CT samples are excluded in the data as the patients were already under glucocorticoid treatment at the time of sample acquisition. Ns, not significant; *P<0.05; **P<0.01; and ***P<0.001

Article Snippet: The first stage antibodies were anti-alpha chain of the IFN alpha/beta receptor (St John’s Laboratory STJ112765) that was used 1:2000 and 1:5000 and anti-Stat1 (1:400, 9175S), anti-pStat1(1:100, 9167S) and anti-Stat2 (1:200, 72604S) all from Cell Signalling.

Techniques: Expressing, Translocation Assay

Journal: Journal of hypertension

Article Title: Apelin Protects Against Angiotensin II-Induced Cardiovascular Fibrosis and Decreases PAI-1 Production

doi: 10.1097/HJH.0b013e32834347de

Figure Lengend Snippet: (A) Apelin decreases PAI-1 mRNA in FFPE cardiac sections from mice receiving either apelin alone, or apelin plus Ang II. (B) Apelin decreases PAI-1 promoter activity at baseline and induced by Ang II, but had no effect on L-NAME-induced PAI-1 promoter activity. CHO cells were transfected with a PAI-1 promoter reporter construct, apelin receptor expression vector, and transfection control plasmid pRLTK. After 48 hours, cells were incubated with apelin (100 nM), Ang II (100 nM), L-NAME (100 μM), or the combination of apelin plus Ang II or apelin plus L-NAME. (C) Apelin decreases PAI-1 mRNA in vitro. HASM cells were treated with Ang II or apelin alone, or in combination for 24h. Results are presented as the relative increase in PAI-1 mRNA compared to saline controls, and normalized to β-actin. (D) Apelin decreases PAI-1 protein production in vitro. Active PAI-1 in HASM cells incubated as described was quantified by ELISA. The data from each experiment is expressed as mean (± S.E.M). *P<0.001 vs vehicle, †P<0.001 vs apelin, ‡P<0.01 vs Ang II by one-way ANOVA with Bonferroni’s Multiple Comparison Test.

Article Snippet: Plasminogen activator inhibitor type-1 (PAI-1) antigen was also measured with a commercially available ELISA Kit (Molecular Innovations, Novi, MI).

Techniques: Activity Assay, Transfection, Construct, Expressing, Plasmid Preparation, Incubation, In Vitro, Enzyme-linked Immunosorbent Assay

Journal: Theranostics

Article Title: Neutrophil-like pH-responsive pro-efferocytic nanoparticles improve neurological recovery by promoting erythrophagocytosis after intracerebral hemorrhage.

doi: 10.7150/thno.90370

Figure Lengend Snippet: Figure 4. The mechanisms of pro-efferocytic action and the regulation of proinflammatory microenvironment by D&G@NPEOz NPs in vitro. (A) Western blot images showing the expression levels of ABCA-1, ADAM17, ABCG-1 in BV2 cells with different formulations treatment. (B-C) The levels of sMERTK and sAXL in the culture media of BV2 cells with different formulations treatment, evaluated using ELISA. (D) Representative flow cytometry histogram and quantitative analysis of CD16/32 (a M1 marker) expression on BV2 cells with different formulations treatment (n = 3). (E) Representative flow cytometry histogram and quantitative analysis of CD206 (a M2 marker) expression on BV2 cells with different treatment (n = 3). (F-H) The levels of TNF-α, IL-β and IL-10 in the culture media of BV2 cells with different formulations treatment, evaluated using ELISA (n = 3). All data are presented as means ± SD. # versus ICH + PBS group, ##P < 0.01, ### P < 0.001; * versus indicated groups, *P < 0.05, **P < 0.01, *** P < 0.001.

Article Snippet: IL-10, TNF-α, IL-β, MERTK and AXL ELISA Kits were purchased from Boster Biological Technology, China.

Techniques: In Vitro, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Marker

Journal: Hepatic Oncology

Article Title: Systemic therapy for hepatocellular carcinoma

doi: 10.2217/hep.13.10

Figure Lengend Snippet: Summary of some of the targeted therapies explored in hepatocellular carcinoma to date.

Article Snippet: There are two ongoing Phase II trials of axitinib (potent multitarget tyrosine kinase inhibitor of VEGFR1–3, PDGF and c-KIT), in second-line treatment of patients with advanced HCC [108,109] .

Techniques: Adjuvant, Histone Deacetylase Assay

Journal: Advanced drug delivery reviews

Article Title: Progress in tumor-associated macrophage (TAM)-targeted therapeutics

doi: 10.1016/j.addr.2017.04.010

Figure Lengend Snippet: Selected compilation of drugs in clinical trials whose mechanisms of action may involve modulation of macrophages/TAMs

Article Snippet: Pexidartinib/PLX3397 (Oral c-fms/KIT/FLT3 tyrosine kinase inhibitor) , Centre Leon Berard and Plexxikon, AstraZeneca , 1 Ongoing , Advanced/metastatic colorectal or pancreatic cancer , With Durvalumab (Anti-PD-L1 antibody) , NCT02777710 , May 12, 2016.

Techniques: Clinical Proteomics, Mutagenesis, Inhibition, Variant Assay